The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- Overdose deaths from fentanyl combined with stimulants increased 50-fold since 2010.
- Sober socializing, a growing movement in New Jersey.
- Register for the NJ ACTS Biostatisics, Epidemiolgy, Research Design Workshop Series on 10/19 for
- Op-Ed: Stand up for cancer patients, innovation and access to life-saving therapies
- New NJACTS Publication